|
Volumn 3, Issue 3, 2001, Pages 142-146
|
Future of adenoviruses in the gene therapy of arthritis
|
Author keywords
Gene expression; Gene therapy; Immunity; Vector; Virus
|
Indexed keywords
CYTOKINE;
GANCICLOVIR;
GENE PRODUCT;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
IMMUNOSUPPRESSIVE AGENT;
INTEGRIN;
INTERLEUKIN 1;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
MACROGOL;
MITOGEN ACTIVATED PROTEIN KINASE;
ORNITHINE CARBAMOYLTRANSFERASE;
THYMIDINE KINASE;
TUMOR NECROSIS FACTOR ALPHA;
VIRUS DNA;
VIRUS PROTEIN;
VIRUS VECTOR;
ADENO ASSOCIATED VIRUS;
ADENOVIRUS;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTHRITIS;
CHIMERA;
CONTROLLED STUDY;
DRUG ACTIVITY;
DRUG SAFETY;
EXPERIMENTAL ANIMAL;
GENE EXPRESSION;
GENE TARGETING;
GENE THERAPY;
GENETIC CODE;
GENETIC ENGINEERING;
GENOME;
HUMAN;
IN VIVO STUDY;
LABORATORY TEST;
MOUSE;
NONHUMAN;
NOTE;
SYNOVIUM;
TRANSGENE;
VIRUS CHARACTERIZATION;
VIRUS GENE;
VIRUS INFECTION;
VIRUS RECOMBINANT;
ADENOVIRUSES, HUMAN;
ARTHRITIS, RHEUMATOID;
GENE EXPRESSION;
GENE THERAPY;
GENETIC VECTORS;
HUMANS;
OSTEOARTHRITIS;
RECOMBINATION, GENETIC;
|
EID: 0035049849
PISSN: 14659905
EISSN: None
Source Type: Journal
DOI: 10.1186/ar291 Document Type: Note |
Times cited : (32)
|
References (40)
|